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Efﬁcacy of Long-Term Remote Ischemic Conditioning on Vascular and
Neuronal Function in Type 2 Diabetes Patients With Peripheral
Arterial Disease
Christian S. Hansen, MD, PhD; Marit E. Jørgensen, MD, PhD; Jesper Fleischer, PhD; Hans Erik Bøtker, DMsc, MD; Peter Rossing, DMsc, MD
Background-—Peripheral artery disease is a major socioeconomic challenge in the diabetes mellitus community and non-surgical
treatment options are limited. As remote ischemic conditioning (RIC) improves vascular function and attenuates ischemia-induced
tissue damage, we investigated the efﬁcacy of RIC on vascular and neuronal function in type 2 diabetes mellitus patients with
peripheral artery disease.
Methods and Results-—We enrolled 36 type 2 diabetes mellitus patients with moderately reduced toe pressure (40–70 mm Hg) in
a randomized sham-controlled double-masked trial. Patients were allocated to 12 weeks once daily upper arm cuff-based
treatment of either RIC treatment (4 cycles of 5-minute ischemia followed by 5-minute reperfusion) or similar sham-device
treatment. Primary outcome was transcutaneous tissue oxygen tension of the instep of the feet. Secondary outcomes were aortic
pulse wave velocity, toe pressure and toe-brachial index. Tertiary outcomes were markers of peripheral and autonomic nerve
function. We enrolled 36 patients (83% men). Patients had a mean (SD) age of 70.7 years (6.8), diabetes mellitus duration of
18.4 years (8.3), HbA1c (gycated hemoglobin) of 59.7 mmol/mol (11.2). Eighty percent had peripheral symmetrical neuropathy.
The mean difference in change of transcutaneous tissue oxygen tension from baseline between the RIC and sham-treated groups
was 0.03 mm Hg ([95% CI 0.1; 0.04], P=0.438). RIC did not elicit any change in additional outcomes. Three patients
experienced transient skin petechiae in the treated arm.
Conclusions-—Long-term repeated remote ischemic conditioning treatment have no effect on tissue oxygenation, vascular or
neuronal function in patients with type 2 diabetes mellitus and moderate peripheral artery disease.
Clinical Trial Registration-—URL: http://www.ClinicalTrials.gov. Unique identiﬁer: NCT02749942. ( J Am Heart Assoc. 2019;8:
e011779. DOI: 10.1161/JAHA.118.011779.)
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• vascular function
P eripheral artery disease (PAD) is a major challenge in thediabetes mellitus community. The prevalence of PAD in
patients with diabetes mellitus exceeds that of non-diabetic
individuals and is estimated to be 26% in individuals aged
>65 years progressing to 71% in the age range >70 years.1
PAD is the major cause of foot ulcers and lower extremity
amputations. PAD has important socioeconomic implications
and is considered the most expensive complication to
diabetes mellitus.2 The main treatment option for PAD is
surgical and endovascular revascularisation,3 which is asso-
ciated with increased rates of complications and mortality in
diabetes mellitus patients.4 Although pharmacological treat-
ment with anti-platelet drugs in patients with PAD has shown
beneﬁcial effect on walking distance,5 they have not been
endorsed as standard treatment for PAD. No other evidence-
based treatment options are currently available. Hence, new
treatment options are urgently needed for individuals with
diabetes mellitus and PAD.
Remote ischemic conditioning (RIC) is a non-invasive non-
pharmacological treatment that attenuates tissue damage
caused by ischemia-reperfusion injury. RIC has been shown
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capable of reducing infarct size in patients with acute
myocardial infarction,6 reducing organ damage in patients
undergoing kidney transplantation7 and to have neuroprotec-
tive effects in patients with stroke.8 RIC is achieved by brief
repetitive periods of ischemia induced in an extremity eg, an
arm. It is believed that the effect of RIC is mediated through
both neuronal and humoral pathways. In addition to the effect
on ischemia-reperfusion injury, RIC has been shown to have
beneﬁcial effects by attenuating platelet activation and
aggregation,9 improving endothelial function,10 and improving
microcirculation.11
Only few studies have investigated the efﬁcacy of long-
term RIC treatment. These studies have demonstrated that
home-based long-term treatment is feasible and that it could
improve endothelial function and microcirculation in healthy
individuals, reduce the recurrence of stroke in patients with
prior stroke12 and increase muscle strength and decrease
blood pressure in patients with chronic heart failure.13 No
studies have yet investigated the effect of long-term RIC in
diabetes mellitus patients. The acute effect of a single RIC
treatment on walking distance in non-diabetic patients with
claudication14 has demonstrated a trend towards improve-
ment. However, the results were inconclusive because of
small sample sizes. We hypothesized that RIC treatment for
an extended period has beneﬁcial effects on the predominant
pathophysiological components, vascular and neuronal dam-
age, underlying PAD2 by attenuating the pathophysiological
processes in the micro- and macro-vasculature related to
PAD.
The aim of the present study was to investigate the
efﬁcacy and safety of 12 weeks of RIC treatment once daily in
patients with type 2 diabetes mellitus and moderate PAD.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Design
The study was a single-center randomized double-masked
sham-controlled trial performed at Steno Diabetes Center
Copenhagen (Gentofte, Denmark). Inclusion criteria were:
(1) type 2 diabetes mellitus, (2) aged 40 to 80 years, (3)
and toe pressure between 40- and 70-mm Hg. Exclusion
criteria were: (1) active foot ulcer, (2) peripheral gangrene
or infection, (3) heart failure: NYHA (New York Heart
Association) class III and IV, (4) pregnancy, (5) cancer, or
(6) treatment for chronic obstructive pulmonary disease.
Patients were recruited from the outpatient clinic of Steno
Diabetes Center Copenhagen. Patients were identiﬁed from
the patient database at Steno Diabetes Center Copenhagen.
Patients with conﬁrmed symptoms of claudication and/or
toe pressures between 40 and 70 mm Hg were contacted
by mail or telephone and invited to the ﬁrst study visit,
where ﬁnal eligibility was assessed by interview and toe
pressure assessment. All patients gave written informed
consent. The study conformed to the Declaration of
Helsinki and the study protocol was approved by the local
Danish ethics committee (ID H-15019400) and the data
protection agency (SDC 2015-47) and registered at Clinica
lTrials.gov (ID NCT02749942).
Intervention
Patients were randomized to 12-week once daily self-
administered cuff-based treatments of either 4 cycles of 5-
minute forearm ischemia/reperfusion with a cuff pressure of
200 mm Hg or 4 cycles of 5-minute sham device treatment
with a cuff pressure of 0 mm Hg. Patients did not receive
treatment on the day examination.
At the initial pre-study visit, patients were screened for
eligibility by an interview and toe pressure measurement.
Eligible patients were randomized as stated below. Random-
ized patients were subjected to 5 subsequent study visits:
baseline (randomization), after 1, 4, and 12 weeks of
treatment and 4-week post-treatment. All outcomes measures
Clinical Perspective
What Is New?
• Peripheral artery disease is a major socioeconomic chal-
lenge in the diabetes mellitus community where remote
ischemic condition may serve as a new treatment modality
for peripheral artery disease.
• Thirty-six type 2 diabetes mellitus patients with moderately
reduced toe pressure were enrolled in a randomized
placebo-controlled double-masked trial, investigating the
effect of 12 weeks once daily upper arm cuff-based
treatment of either remote ischemic condition treatment
(4 cycles of 5-minute ischemia followed by 5-minute
reperfusion) or similar sham device treatment on vascular
and neuronal outcomes.
• Long-term repeated remote ischemic conditioning treat-
ment had no effect on tissue oxygenation, vascular or
neuronal function in patients with type 2 diabetes mellitus
and moderate peripheral artery disease.
What Are the Clinical Implications?
• We show that home-treatment is feasible and safe.
• Remote ischemic conditioning may, however, not be
efﬁcacious in patients with diabetes mellitus and
neuropathy.
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were collected at baseline, after 4 and 12 weeks of treatment
and 4 weeks post-treatment. Toe pressure measurements
were only performed at screening and end of treatment (week
12). At study visit one (week after treatment initiation) all
measures besides toe pressure, arterial stiffness and cardio-
vascular reﬂex tests (CARTs) were collected.
Randomization
Patients were randomly assigned (1:1) in blocks of 4 to
receive either active cuff-based RIC treatment by an auto-
mated RIC device (the reusable fully automated RIC device
“AutoRIC”, CellAegis Devices, Canada) or cuff-based sham
treatment by a similar automated sham RIC device. A third-
party researcher not afﬁliated with the trial at Steno Diabetes
Center Copenhagen constructed a computer-generated ran-
domization list. To ensure the double-masked design, devices
were packed in boxes and consecutively allocated to trial
patients in concordance with the randomization list by a third-
party researcher not afﬁliated with the study. The personnel
responsible for randomization and devices had no further
involvement in the trial. Active and sham devices were
indistinguishable from each other and yielded identical
sounds by use. Study staff was masked to treatment
allocations. During the trial patients were asked to report
severe discomfort to treatment. To prevent unmasking, trial
staff did not ask about other discomfort.
Outcomes
The primary outcome of the trial was change in transcuta-
neous tissue oxygen tension (TcPO2) of the dorsal part of the
foot from baseline to 12 weeks of treatment measured by the
Periﬂux 6000 system (Perimed, Sweden). The primary end
point was chosen to be tissue oxigination as this was
assessed to be the most direct measures of vascularization in
the end-organ tissue. Adhesive TcPO2 electrode were
attached to the skin 3.5 cm proximately from the root of
the third toe on both feet. The position of the electrode was
photographed to ensure identical electrode position at the
following study visits. Probes were heated to 44°C and TcPO2
levels were recorded as a mean of oxygen levels from 15 to
16 minutes when plateau was reached.
Secondary outcome variables
Aortic (carotid–femoral) pulse wave velocity (PWV) was
measured using SphygmoCor (AtCor Medical, Sydney, Aus-
tralia). PWV was calculated as the time delay between carotid
and femoral pulsation divided by the distance between the
carotid and femoral arteries multiplied by 0.8.15 Three PWV
measurements were recorded and averaged. Systolic blood
pressure in the ﬁrst toe on each foot was measured by strain
gauge technique by the Digimatic DM2000 device (Medimatic,
Hellerup, Denmark). Feet were preheated for 10 minutes by
an electric heat blanket. Toe/brachial index was calculated by
dividing the mean of 2 systolic toe pressure measurements
with the mean of 2 systolic blood pressure measurements.
PWV was chosen as a secondary outcome because previous
studies affecting risk factors for reduced PWV such as
inﬂammation16 has been demonstrated to be improved by RIC
treatment.17 Toe pressure was chosen as an outcome
because potential risk factors for reduced toe pressure such
as inﬂammation and increased platelet activation and aggre-
gation and reduced endothelial function was been shown to
be improved be RIC treatment.8,10 Both outcomes are
established markers of cardiovascular disease.
Tertiary outcome variables
Trained technicians used a Vagus device (Medicus Engi-
neering, Aarhus, Denmark) to quantify cardiovascular auto-
nomic neuropathy. Indices of 5-minute supine resting heart
rate variability and the 3 standard cardiac autonomic reﬂex
tests (CARTs) recommended for diagnosing cardiovascular
autonomic neuropathy18 were performed: the lying-to-
standing test (30/15), the deep breathing test (E/I ratio)
and the Valsalva maneuver. CARTs were performed in the
mentioned order and in accordance with procedures as
described previously.19 CARTs and heart rate variability
measures were analyzed as continuous variables. We used
age-dependent cut-off levels18 to deﬁne pathological results
of the CARTs. The cardiovascular autonomic neuropathy
diagnosis was deﬁned as the presence of 2 or 3 patholog-
ical CARTs.
Peripheral small-ﬁber autonomic function was assessed by
electrochemical skin conduction test on the hands and feet by
the Sudoscan device (Impeto Medical, Paris, France). Age and
sex stratiﬁed electrochemical skin conduction thresholds for
hands and feet were used.20 Sural nerve conduction velocity
and sural nerve action potential (SNAP) were measured using
the handheld NC-Stat DPNCheck (NeuroMetrix, Inc, Waltham,
USA). Age and height stratiﬁed threshold limits for sural nerve
action potential and sural nerve conduction velocity were
applied to identify abnormal results.21
Vibration perception threshold was determined using a
Bio-Thesiometer (Bio-Medical Instruments, OH, USA) at the
distal end of the great toe on both feet. Age stratiﬁed
perception thresholds were used to determine pathological
vibration perception threshold.22 Light touch perception was
assessed by applying a 10-g monoﬁlament to 3 points at the
footpads just proximal to the ﬁrst, third, and ﬁfth toe. Pain
sensation assessment was performed using a 40-g pin-prick
device (Neuropen; Owen Mumford Ltd, Oxford, UK) applied
at the dorsal side of the ﬁrst, third, and ﬁfth toe just
proximal to the nail on both feet. We applied Neuropen
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assessments 3 times at each point and conﬁrmed sensation
only when the patient indicated sensation at all 3 stimuli.
Symptoms of peripheral neuropathy were assessment by a
composite score of the Minnesota Neuropathy Screening
Instrument (MNSI) questionnaire. A score >6 was deﬁned as
peripheral neuropathy.
All examinations were performed in a quiet setting at room
temperature (18°C –23°C) between 8 AM and 12 AM. Patients
started fasting at midnight before testing, refrained from
smoking on the day of examination, and avoided strenuous
exercise 24 hours before examination. Patients did not take
any medication on examination days.
Neuropathy outcomes were chosen as exploratory out-
comes because diabetic neuropathy is a serious complication
to diabetes mellitus which could be affected by RIC treatment,
as RIC has been demonstrated to improve measures of
microcirculation11 which could affect nerve function directly.
Also, a RIC-induced reduction in systemic inﬂammation (as
mentioned above) could improve nerve function.
Anthropometric Variables
Height and weight were measured with light indoor clothing,
without shoes, using a ﬁxed rigid stadiometer (Seca, Chino,
Figure 1. Trial proﬁle. RIC indicates remote ischemic conditioning.
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Table 1. Baseline Characteristics
RIC Treatment
(n=18) Sham (n=17)
P for Group
Difference
Sex (male), n/% 14/77.8 15/88.2 0.407
Age, y 71.1 (5.5) 70.2 (8.1) 0.697
HbA1c, mmol/mol 56.9 (7.8) 62.6 (13.6) 0.110
HbA1c (%) 7.4 (0.7) 7.9 (1.2) 0.110
Body mass index, kg/m2 32.0 (5.3) 30.8 (4.9) 0.465
Weight, kilo 93.0 (17.6) 90.9 (10.2) 0.664
Current smoker, n/% 3/16.7 5/29.4 0.364
No exercise, n/% 6/33.3 6/35.3 0.903
Systolic blood pressure, mm Hg 145.7 (11.4) 151.9 (17.5) 0.202
Diastolic blood pressure, mm Hg 76 (7.8) 76.1 (8.2) 0.982
Diabetes mellitus duration, y 19.2 (6.4) 17.5 (9.9) 0.525
Myocardial infarction, self-reported, n/% 3/16.7 5/29.4 0.364
Cerebral infarction, self-reported, n/% 3/16.7 5/29.4 0.364
Thrombosis in leg, self-reported, n/% 0/0 3/17.6 n/a
Impaired sural nerve conduction, n/%* 13/100 8/61.5 0.004
Impaired sudomotor function feet,
bilateral, n/%
13/72.2 13/81.3 0.533
Impaired sudomotor function hands,
bilateral, n/%
7/38.9 8/50 0.512
Impaired vibration
sensation, bilateral, n/%
9/69.2 15/88.2 0.185
Monofilament sensation (total of 8, both feet) 4.7 (3.6) 6.1 (3.1) 0.209
Pain (Pin prick) sensation (total of 6, both feet) 3.7 (2.4) 4.1 (2.1) 0.642
Peripheral neuropathy
(MNSI count >6), n/%
7/41.2 1/9.1 0.050
Cardiovascular autonomic
neuropathy diagnosis, n/%
4/26.7 0/0 n/a
Claudication (Edinburgh
claudication questionnaire)
3/16.7 4/23.5 0.611
Mean great toe pressure, mm Hg 61.4 (15.7) 61.2 (15.0) 0.967
Mean toe brachial index 0.4 (0.3–0.5) 0.4 (0.3–0.5) 0.744
eGFR, mL/min per 1.73 m2 55.0 (40.7–73.5) 61.9 (52.5–68.5) 0.668
Urinary albumin excretion rate (mg/24-h) 27 (14–195) 57 (22–285) 0.393
Total cholesterol, mmol/L 3.4 (3.1–4.4) 4.0 (3.5–4.7) 0.112
HDL cholesterol, mmol/L 1.1 (0.3) 1.1 (0.1) 0.540
LDL cholesterol, mmol/L 1.7 (1.2–2.2) 2.1 (1.4–2.8) 0.228
Triglycerides cholesterol, mmol/L 1.6 (1–2.6) 2.0 (1.2–3.2) 0.194
Medication
Beta blocker, n/% 10/55.6 7/41.2 0.390
Diuretic, n/% 5/27.8 5/29.4 0.915
RAAS blocker, n/% 7/38.9 6/35.3 0.826
Statins, n/% 15/83.3 12/70.6 0.364
Calcium antagonists, n/% 8/44.4 7/41.2 0.845
Continued
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USA) and an electronic scale (Mettler Toledo, Glostrup,
Denmark), respectively.
Blood Pressure
Oscillometric (A&D Medical, UA787) ofﬁce blood pressure
was measured in a supine position after 15 minutes rest
using an appropriate cuff size. Three measurements were
obtained and averaged.
Biochemical Variables
HbA1c was analyzed by high-performance liquid chromatog-
raphy on a Tosoh G7 (Tosoh Corporation, Japan). High density
lipoprotein and total cholesterol were analyzed by standard
enzymatic colorimetry techniques. Creatinine was analyzed by
2-point rate enzymatic technique. Urinary albumin excretion
ratio was measured in morning spot urine collections by an
enzyme immunoassay. Urinary albumin was analyzed by
quantitative immunological turbidimetry.
All analyses except for HbA1c were done on a Vitros 5600
(Orhto Clinical Diagnostics, France). Chronic Kidney Disease
Epidemiology Collaboration Equation was used to calculate
the estimated glomerular ﬁltration rate from p-creatinine.
Lifestyle Variables
Lifestyle measures were obtained by questionnaires. Patients
were classiﬁed as current smokers when using ≥1 cigarettes
or cigars or pipes per day. Physical activity was deﬁned as
being regularly physically active or not.
Compliance
Compliance was monitored at every study visit by obtaining
the number of treatments through a compliance monitoring
system embedded in the cuffs and read by a wireless monitor
unit.
Statistical Analyses
Power calculation
We hypothesized that RIC treatment would increase tissue
oxygen tension in the feet (primary outcome) by 13%
(SD=10%), which is an 30% smaller effect than previously
demonstrated in healthy volunteers.23 With 90% power and a
2-sided signiﬁcance level of 0.05 the sample size needed to
detect this change is 14 in each group or 28 patients in total.
Expecting a dropout rate of 10% the sample size of the study
was calculated to be 16 patients in each group.
Patient characteristics are presented as means (SD), as
medians with interquartile ranges or as percentages. Group
differences in baseline variables were assessed by t test and
Chi-square test for categorical variables. Associations were
modeled by linear mixed-effect models with a patient-speciﬁc
random intercept to account for the correlation of repeated
measurements within patients using the proc GLIMMIX
procedure with “variance components” as covariance struc-
ture. All analyses were performed as an intention-to-treat
analysis. To fulﬁll the requirement of a normal distribution of
the model residuals, outcomes were log-transformed when
applicable. Consequently, estimates for these models are
given in percentages. Heart rate variability indices were
adjusted for 5-minute resting heart rate at the time of testing
Table 1. Continued
RIC Treatment
(n=18) Sham (n=17)
P for Group
Difference
Any lipid lowering, n/% 16/88.9 15/88.2 0.952
Glp1-receptor agonist, n/% 8/44.4 4/23.5 0.182
DPP4 inhibitor, n/% 2/11.1 6/35.3 0.075
SGLT-2 inhibitor, n/% 1/5.6 5/29.4 0.048
Metformin, n/% 14/77.8 12/70.6 0.626
Long-acting insulin, n/% 10/55.6 9/52.9 0.877
Intermediate-acting insulin, n/% 1/5.6 3/17.6 0.252
Fast-acting insulin, n/% 11/61.1 8/47.1 0.400
Vitamin K antagonists, n/% 2/11.1 1/5.9 0.579
Acetylsalicylic acid, n/% 2/11.1 3/17.6 0.579
Antiplatelet drugs, n/% 4/22.2 6/35.3 0.387
Data are in means (SD), medians (interquartile ranges) or n (%). eGFR indicates estimated glomerular ﬁltration rate (mL/min per 1.73 m2); HDL, high-density lipoprotein; LDL, low-density
lipoprotein; MNSI, Michigan Neuropathy Screening Instrument questionnaire; RAAS, renin angiotensin aldosterone system; HbA1c, Glycated Heemoglobin; Glp 1, Glucagon Like Peptide 1;
DPP4, dipeptidyl peptidase 4; SGLT-2, Sodium-glucose co-transporter 2.
*Where measures were achievable.
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and PWV measures were adjusted for mean arterial blood
pressure. Additional exploratory adjustments were done for
relevant baseline confounders where signiﬁcant or near-
signiﬁcant between group differences were found. Statistical
signiﬁcance was inferred at a 2-tailed P<0.05. All analyses
including the power calculation were performed using SAS
version 9.4 (SAS Institute, Cary, NC).
Results
We tested 1806 patients at the initial screening of patient
records. A total of 1660 did not meet the screening inclusion
criteria. We invited 146 patients, of whom 65 declined the
invitation. We screened 81 patients at the ﬁrst study visit. Of
these, 45 did not meet inclusion criteria because toe pressure
measurements were beyond the inclusion range. A total of 36
patients were enrolled in the study and randomized to either
active treatment or sham in equal proportions. We allocated
18 patients to active treatment and 18 to sham. One patient
in the active arm discontinued treatment because of side
effects but stayed in the study. One patient in the sham group
withdrew consent before the second study visit, thus 34
patients completed the study (Figure 1).
Baseline data for the RIC and the sham group are shown in
Table 1. Overall, 83% of patients were men, had a mean (SD)
age of 70.7 years (6.8), a diabetes mellitus duration of
18.4 years (8.3), a toe pressure of 61.3 mm Hg (15.1), a
TcPO2 for both feet of 51.3 mm Hg (10.7), an HbA1c of
Table 2. Baseline Characteristics for Outcome Variables
Randomization
Active Treatment Sham Treatment
P Value for Group
Difference
Primary outcome
Transcutaneous oxygen tension, right foot (mm Hg) 50.6 (10.1) 49.0 (6.8) 0.580
Transcutaneous oxygen tension, left foot (mm Hg) 50.9 (11.4) 52.3 (13.5) 0.732
Transcutaneous oxygen tension, mean (mm Hg) 50.8 (9.9) 51.8 (11.8) 0.763
Secondary outcomes
Pulse wave velocity, m/s 14.0 (3.1) 13.3 (3.4) 0.487
Toe pressure, mean (mm Hg) 61.4 (15.7) 61.2 (15.0) 0.967
Toe brachial index, mean 0.41 (0.31–0.48) 0.36 (0.33–0.45) 0.684
Tertiary outcomes
E/I ratio 1.06 (1.04–1.23) 1.11 (1.09–1.2) 0.929
30/15 ratio 1.06 (1.02–1.13) 1.06 (1.03–1.11) 0.810
Valsalva 1.20 (1.13–1.25) 1.22 (1.1–1.43) 0.607
SDNN, ms 18.85 (11.3–38.9) 28.7 (20.8–50.5) 0.219
RMSSD, ms 13.55 (7.05–26.00) 21.6 (10.8–65.9) 0.217
Total power, ms2 156.89 (43.68–551.86) 294.49 (91.86–920.03) 0.223
High frequency power, ms2 38.83 (10.51–226.18) 59.86 (35.62–398.43) 0.336
Low frequency power, ms2 16.06 (6.42–100.05) 38.52 (11.23–246.69) 0.357
LF/HF ratio 1.75 (1.04–3.23) 1.67 (1.30–3.88) 0.802
Electrochemical skin conduction, hands mean (lS) 57.8 (36.5–65.8) 46.0 (38.6–61.1) 0.592
Electrochemical skin conduction, feet mean (lS) 58.9 (27.8–71.8) 54.1 (41.4–64.4) 0.225
Sural nerve conduction velocity, mean (m/s) 35.0 (5.3) 40.4.(5.7) 0.007
Sural nerve amplitude potential, mean (lV) 3.2 (2.3–4.0) 3.1 (2.7–4.4) 0.554
Vibration sensation threshold, mean (V) 24.3 (13.8–33.0) 36.5 (25.3–42.6) 0.050
Monofilament, mean both feet (number of positive responses) 6 (1–8) 8 (5–8) 0.642
Pin prick, mean both feet (number of positive responses) 4 (2–6) 5 (3–6) 0.544
Michigan neuropathy screening instrument (count) 5.7 (2.6) 3.8 (2.6) 0.058
Data are means (SD) or medians (interquartile ranges). 30/15 ratio indicates heart rate response to standing; E/I ratio, heart rate response to deep breathing; HF, high-frequency; LF, low-
frequency; RMSSD, the root mean square of the sum of the squares of differences between consecutive R–R intervals; SDNN, standard deviation of normal-to-normal intervals.
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59.7 mmol/mol (11.2), and 24 patients (80%) had peripheral
symmetrical neuropathy assessed by vibration detection
threshold. The patients did not differ between the 2 groups
for any demographic, anthropometric, cardiometabolic, or
neuropathic variables except for sural nerve conduction
velocity (Tables 1 and 2).
Patients in both groups had high compliance to treatment
applying treatment in 92.1% (SD 13.8) and 82.1% (SD 18.1) of
possible days in the RIC group and the sham group,
respectively, with a borderline signiﬁcant group difference
P=0.059.
RIC did not improve the primary end point signiﬁcantly,
TcPO2 on the dorsal part of the foot, at 12 weeks either when
mean values of both feet were assessed (Figure 2) nor when
each foot was assessed. Mean difference in change in
average TcPO2 from baseline to 12 weeks between groups
was 0.03 mm Hg (95% CI 0.1; 0.04) by assessment on
both feet (P=0.438 [Table 3]). No effect of RIC treatment on
TcPO2 was observed at any other visit during treatment or at
4 weeks post-treatment (Table 4).
Similarly, secondary outcomes were not affected by RIC at
any study visit. At week 12, aortic pulse wave velocity was
unaffected by RIC treatment compared with sham with a
difference in change of 0.07% (95% CI 0.08; 0.22),
(P=0.385) The difference in mean toe pressure for both toes
was 0.04 mm Hg (95% CI 0.2; 0.11) (P=0.603). For mean
toe/brachial index no differences were observed. Group
difference was 0.06% (95% CI 0.28; 0.17) (P=0.627)
(Tables 3 and 4).
Tertiary outcome variables were unaffected by RIC. Central
autonomic variables assessed by cardiovascular autonomic
reﬂex tests and indices of heart rate variability were
unaffected as were peripheral autonomic variables assessed
by electrochemical skin conductance. Peripheral nerve func-
tion was not affected by RIC when assessed by sural nerve
conduction velocity and action potential, vibration sensation
threshold and light touch sensation or when small ﬁber nerve
function was assessed by 40-g pin-prick induced pain
(Tables 3 and 4). RIC did not elicit signiﬁcant changes in
the mean score of the MNSI questionnaire (Tables 3 and 4).
As a signiﬁcant between-group difference in mean sural
nerve conductance velocity was seen at baseline (Table 2),
models for vascular outcomes were additionally adjusted for
this possible confounder for patients with baseline measure of
the confounder. A treatment effect was seen as a reduction in
transcutaneous oxygen tension on the right foot at week 4
and week 12 of 0.36 mm Hg (95% CI 0.59; 0.13)
(P=0.003) and 0.09 mm Hg (95% CI 0.17; 0.01)
P=0.037, respectively. No other treatment effects were seen
in models adjusted for nerve conduction velocity (Table S1). A
borderline signiﬁcant group difference was seen for MNSI
score (Table 2). When models for vascular outcomes were
adjusted for this possible confounder for patients with
baseline measure of the confounder a treatment effect was
seen as an increase in transcutaneous oxygen tension on the
right foot and mean values for both feet at week 1 with an
estimate of 1.08 mm Hg (95% CI 0.26; 1.89) (P=0.016) and
0.95 mm Hg (95% CI 0.2; 1.69) (P=0.019), respectively. No
other treatment effects were seen in models adjusted for
nerve conduction velocity (Table S2). We did not adjust
tertiary neuropathy outcomes further for nerve conductance
velocity or MNSI score as these analyses were adjusted for
baseline measures of the speciﬁc measure of nerve function.
Three patients experienced adverse events in the RIC
treatment group. All patients experienced discomfort during
cuff-induced ischemia, and petechiae (microbleeds in the
skin) appeared distal to the position of the cuff (Figure 3).
Skin changes gradually disappeared within 1 week. No
discomfort was experienced after treatment. All patients
continued treatment on the other arm. One patient discon-
tinued treatment because of reoccurrence of a similar adverse
event on the other arm. None of the patients experienced
persisting deﬁcit, and no other adverse events were observed.
Discussion
The results of the present study demonstrate that home-
based long-term (12 weeks) treatment with repeated RIC is
safe and feasible with remarkable compliance in a sham-
controlled setting. Despite adherence to treatment, RIC did
not signiﬁcantly improve tissue oxygenation or vascular or
neuronal function in the lower extremities.
RIC treatment did not elicit signiﬁcant improvements in
microvascular perfusion of the feet assessed by transcuta-
neous tissue oxygen tension or macrovascular perfusion
assessed by toe pressure and toe-brachial index. It seems
that results from previous studies in non-diabetic cohorts
Figure 2. Treatment effect on transcutaneous oxygen tension.
Effect of treatment (dark blue solid lines) vs sham (light blue
dashed lines) during trial. Data are in mean (SD). No P<0.05 for
group difference at any time point.
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demonstrating beneﬁcial effects of RIC on endothelial func-
tion10 and microcirculation11 cannot be translated into an
effect in diabetes mellitus patients. The paucity of improve-
ments in vascular function in the present study may indicate
that a vital parameter for quality of life in patients with
diabetes mellitus and PAD—walking distance—may not be
improved by RIC treatment as seen in non-diabetic mellitus
individuals without claudication treated for 6 weeks.24
RIC treatment has been shown to affect risk factors for
increased arterial stiffness such16 as markers of inﬂamma-
tion.17 However, arterial stiffness assessed by PWV was not
affected by RIC treatment in our study. Only one study has
investigated the efﬁcacy of RIC treatment on nerve function,
showing that 6 weeks of RIC treatment improved autonomic
function by increasing heart rate variability indices in nondi-
abetic individuals.24 However, we were not able to demon-
strate any beneﬁcial effects on measures of either autonomic
or peripheral nerve function.
The lack of effect of RIC treatment on the outcome
variables applied in this trial may be attributed to several
factors. Treatment duration may be insufﬁcient. Transcuta-
neous oxygen tension has been acutely improved in an acute
study of RIC treatment;23 however, immediate effects may not
extend beyond an acute reaction. However, prolonged RIC
treatment for 6 and 8 weeks in healthy volunteers improved
microvascular function assessed by cutaneous vascular
conductance11 suggesting that RIC may modify microvascular
function with a treatment duration shorter than applied in our
study. Consequently, the treatment duration applied in the
present study should be adequate to detect a response in
microvascular function. Similarly, treatment duration should
be sufﬁcient to detect changes in PWV as several studies have
demonstrated effect of drug intervention within 12 weeks of
treatment.25 In addition, satin-induced improvements in
walking distance in patients with claudication has been seen
after 6 to 12 weeks of treatment,5 suggesting that the
vascular pathophysiology causing PAD may be affected within
the duration of the present study.
We found not treatment effect on neuropathy measures.
Neuropathy per se may attenuate treatment efﬁcacy as
peripheral neuropathy has been associated with reduced
treatment effect.6 RIC stimulation of peripheral sensory
nerves in the effector organ may be a prerequisite for
initiation of a systemic response that is mediated by humoral
or neural pathways.6 However, the impact of neural pathways
remains unknown as cardio protection can be achieved by RIC
in the denervated heart. Indeed, plasma from patients with
diabetes mellitus and peripheral neuropathy has shown to
have no cardioprotective attributes in experimental in vitro
settings.26 Thus, the presence of neuropathy in the majority of
our study population may explain the absent response to RIC.
Sural nerve conductance velocity was marginally lower in theT
ab
le
3.
C
on
tin
ue
d
W
ee
k
1
W
ee
k
4
W
ee
k
12
Ac
tiv
e
Tr
ea
tm
en
t
Sh
am
Ac
tiv
e
vs
Sh
am
D
iff
er
en
ce
in
C
ha
ng
e
Fr
om
Ba
se
lin
e
Ac
tiv
e
Tr
ea
tm
en
t
Sh
am
Ac
tiv
e
vs
Sh
am
D
iff
er
en
ce
in
C
ha
ng
e
Fr
om
Ba
se
lin
e
Ac
tiv
e
Tr
ea
tm
en
t
Sh
am
Ac
tiv
e
vs
Sh
am
D
iff
er
en
ce
in
C
ha
ng
e
Fr
om
Ba
se
lin
e
Pi
n
pr
ic
k,
m
ea
n
bo
th
fe
et
(n
um
be
r
of
po
si
tiv
e
re
sp
on
se
s)
n/
a
n/
a
n/
a
4.
5
(2
.0
–
6.
0)
6.
0
(4
.0
–
6.
0)
0
.6
8%
(
1.
35
–
0
.0
1)
[0
.0
56
]
6.
0 (2
.0
–
6.
0)
6.
0
(4
.0
–
6.
0)
0.
14
%
(
0.
15
–
0.
43
)
[0
.3
53
]
M
ic
hi
ga
n
ne
ur
op
at
hy
sc
re
en
in
g
in
st
ru
m
en
t
(c
ou
nt
)
4.
8
(2
.7
)
4.
1
(2
.6
)
0
.1
3
(
0.
3–
0.
04
)
[0
.1
46
]
5.
5
(2
.4
)
3
(1
.7
)
0
.0
2
(
0.
07
–
0.
04
)
[0
.5
81
]
5.
3
(2
.6
)
4.
3
(3
)
0
.0
1
(
0.
02
–
0.
01
)
[0
.3
91
]
D
at
a
ar
e
m
ea
ns
(S
D
)o
r
m
ed
ia
ns
(in
te
rq
ua
rt
ile
ra
ng
es
).
Es
tim
at
es
of
tr
ea
tm
en
t
ef
fe
ct
ar
e
in
pe
rc
en
ta
ge
s
or
ab
so
lu
te
va
lu
es
(9
5%
C
I)
[P
va
lu
es
fo
r
gr
ou
p
di
ffe
re
nc
e]
.M
od
el
s
ha
ve
be
en
ad
ju
st
ed
fo
r
ba
se
lin
e
va
lu
es
of
th
e
gi
ve
n
ou
tc
om
e.
30
/1
5
ra
tio
in
di
ca
te
s
he
ar
tr
at
e
re
sp
on
se
to
st
an
di
ng
;E
/I
ra
tio
,h
ea
rt
ra
te
re
sp
on
se
to
de
ep
br
ea
th
in
g;
H
F,
hi
gh
-fr
eq
ue
nc
y;
LF
,l
ow
-fr
eq
ue
nc
y;
RM
SS
D
,t
he
ro
ot
m
ea
n
sq
ua
re
of
th
e
su
m
of
th
e
sq
ua
re
s
of
di
ffe
re
nc
es
be
tw
ee
n
co
ns
ec
ut
iv
e
R–
R
in
te
rv
al
s;
SD
N
N
,s
ta
nd
ar
d
de
vi
at
io
n
of
no
rm
al
-t
o-
no
rm
al
in
te
rv
al
s.
DOI: 10.1161/JAHA.118.011779 Journal of the American Heart Association 11
Efﬁcacy of Remote Ischemic Conditioning in T2DM Hansen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on December 19, 2019
treatment group as the only objective measure of neuropathy.
Additional adjustments for conductance velocity for vascular
outcomes showed clinically negligible but statically signiﬁcant
reduction in transcutaneous oxygen tension in the right foot
induced by RIC treatment. Similar effects were not seen for
the other foot or means oxygen tension measures or other
outcomes. When adjusting for MNSI-count RIC treatment was
associated with a small but statically signiﬁcant improvement
in transcutaneous oxygen tension at week 1. No effect of
treatment was seen at other timepoints or other outcomes.
We estimate that these ﬁndings are spurious, and that lack of
treatment effect may be because of other factors than
differences in nerve function in the 2 study arms.
The lack of treatment effect may be attributed to the
extent of vascular damage present in the cohort. Despite
having only moderately reduced toe pressure between 40 and
70 mm Hg, patients may have progressed beyond a point of
reversibility by any treatment modality. In addition, the
relative long diabetes mellitus duration of the study popula-
tion may also reduce the effect of RIC, as duration of disease
is associated with diminished treatment efﬁcacy.27
Whether diabetes mellitus per se attenuates RIC efﬁcacy is
not clear.
Patients with PAD may experience transient ischemic
episodes when physically active and therefore may be
preconditioned and thus have no additional effect of RIC.
Table 4. Effect of Trial Post-Treatment
Week 4 Post-Treatment
Active Treatment Sham
Active vs Sham Difference in
Change From Week 12
Primary outcome
Transcutaneous oxygen tension, right foot (mm Hg) 51.6 (8.4) 49.8 (9.7) 0.11 (0.09–0.31) [0.285]
Transcutaneous oxygen tension, left foot (mm Hg) 52.6 (9.1) 46.2 (14.5) 0.08 (0.16–0.32) [0.511]
Transcutaneous oxygen tension, mean (mm Hg) 52.1 (7.7) 48.8 (11.8) 0.08 (0.09–0.25) [0.359]
Secondary outcomes
Pulse wave velocity, m/s 15.0 (4.5) 15.0 (4.5) 0.11% (0.84–0.62) [0.766]
Toe pressure, mean (mm Hg) n/a n/a n/a
Toe brachial index, mean n/a n/a n/a
Tertiary outcomes
E/I ratio 1.06 (1.03–1.19) 1.06 (1.04–1.24) 0.02% (0.4–0.36) [0.914]
30/15 ratio 1.02 (1–1.07) 1.1 (1.02–1.13) 0.11% (0.25–0.02) [0.104]
Valsalva 1.2 (1.12–1.27) 1.2 (1.12–1.25) 0.27% (0.84–0.29) [0.359]
SDNN, ms 17.8 (8.7–49.8) 21.3 (14.7–32.6) 1.28% (0.04–2.62) [0.07]
RMSSD, ms 15.1 (7.5–34.9) 17.3 (10.3–27.7) 1.23% (0.59–3.07) [0.200]
Total power, ms2 104.65 (21.37–831.8) 155.76 (83.88–415.59) 1.86% (1.08–4.89) [0.230]
High frequency power, ms2 25.42 (2.65–387.59) 48.97 (13.28–118.14) 1.84% (2.38–6.23) [0.408]
Low frequency power, ms2 10.84 (5.09–123.17) 33.1 (14.63–54.83) 1.31% (2.5–5.27) [0.514]
LF/HF ratio 1.4 (0.36–3.31) 0.97 (0.67–1.95) 0.63% (1.35–2.64) [0.545]
Electrochemical skin conduction, hands mean (lS) 40.5 (29–6.75.0) 55.8 (36.3–61.3) 0.40% (1.01–0.22) [0.217]
Electrochemical skin conduction, feet mean (lS) 46.3 (27.5–63.5) 51.0 (31.8–61.3) 0.44% (1.08–0.2) [0.191]
Sural nerve conduction velocity, mean (m/s) 37.6 (4.3) 40.3 (7.8) 0.04% (0.60–0.51) [0.875]
Sural nerve amplitude potential, mean (lV) 3.7 (2.7–4.5) 3.3 (2.7–4.7) 0.83% (0.05–1.62) [0.048]
Vibration sensation threshold, mean (V) 28.5 (20.5–43) 34.8 (30.0–39.0) 0.36% (1.45–0.74) [0.529]
Monofilament, mean both feet (number of positive responses) 7.0 (0.0–8.0) 7.0 (4.0–8.0) 0.11% (0.84–0.62) [0.766]
Pin Prick, mean both feet (number of positive responses) 6.0 (2.0–6.0) 6.0 (3.0–6.0) 0.41% (1.62–0.82) [0.519]
Michigan neuropathy screening instrument (count) 5.1 (2.9) 5.1 (3.4) 0.03 (0.08–0.02) [0.197]
Data are means (SD) or medians (IQR). Estimates of treatment effect are in percentages or absolute values (95% CI) [P values for group difference]. Models have been adjusted for values at
week 12 of the given outcome. 30/15 ratio indicates heart rate response to standing; E/I ratio, heart rate response to deep breathing; HF, high-frequency; LF, low-frequency; RMSSD, the
root mean square of the sum of the squares of differences between consecutive R–R intervals; SDNN, standard deviation of normal-to-normal intervals.
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However, intermittent claudication was not associated with
reduced mortality in a study of patients with myocardial
infarction,28 indicating that patients with PAD may not
experience preconditioning as a consequence of their
atherosclerotic disease.
The number of study participants may have been insufﬁ-
cient to show an effect of treatment. The power calculation
was based on an expected effect in the primary outcomes
<30% than seen in healthy volunteers. This could have been
an overestimation of the effect in diabetes mellitus patients
with PAD.
Safety
Compliance to treatment protocol was remarkably high with
compliance rates of 92.1% in the RIC group and 82.1% in the
sham group. Three adverse events of transient skin petechiae
distally to cuff placement were observed in the RIC group. All 3
patients were treated with acetylsalicylic acid. Adverse events
were transient, and no permanent deﬁcits were observed.
Conclusion
Our study shows that in patients with type 2 diabetes mellitus
and moderate peripheral artery disease 12-week repeated
remote ischemic conditioning treatment had no effect on
tissue oxygenation, vascular or neuronal function despite
remarkable compliance to treatment.
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Data are means (SD) or medians (IQR). Estimates of treatment effect are in % or absolute values (95% CI) [P values] for group difference. Models have been adjusted for baseline values of the given 
outcome and for mean sural nerve conduction velocity at baseline.  
Table S1. Effect of trial additionally adjusted for baseline sural nerve conductance velocity. 
Week 1 Week 4 Week 12 
Active 
treatment  
Placebo 
Active 
vs. 
Placebo 
differen
ce in 
change 
from 
baseline 
Active 
treatment  
Placebo 
Active vs. Placebo 
difference in change 
from baseline 
Active 
treatment  
Plac
ebo 
Active vs. Placebo difference in 
change from baseline 
Primary outcome 
 
Transcutaneous oxygen tension, 
right foot (mmHg) 
50.8 (9.8) 46.7 (11.3) 0.24 (-
0.59; 
1.08) 
[0.571] 
45.8 (14.4) 53 (10.8) -0.36 (-0.59; -0.13) 
[0.003] 
47.9 (13.4) 50.7 
(8.1
) 
-0.09 (-0.17; -0.01) 
[0.037] 
Transcutaneous oxygen tension, 
left foot (mmHg) 
50.4 (11.2) 48.5 (12.4) 0.44 (-
0.35; 
1.22) 
[0.283] 
50.5 (10.5) 54.2 (10.3) -0.07 (-0.31; 0.16) 
[0.547] 
51.2 (9.6) 51.5 
(9.5
) 
-0.01 (-0.09; 0.07) 
[0.776] 
Transcutaneous oxygen tension, 
mean (mmHg) 
50.6 (9.2) 48.5 (12.2) 0.43 (-
0.27; 
1.13) 
[0.243] 
48.1 (11.7) 54.3 (8.9) -0.17 (-0.38; 0.03) 
[0.105] 
49.5 (10) 51.8 
(8.6
) 
-0.04 (-0.11; 0.03) 
[0.228] 
Secondary outcomes 
 
Pulse wave velocity (m/s) n/a n/a n/a 13.6 (3.9) 13.2 (3.4) -0.15% (-0.49; 0.19) 
[0.402] 
14.7 (3.7) 13.3 
(3.3
) 
0.06% (-0.06; 0.19)  
[0.313] 
Toe pressure, mean (mmHg) n/a n/a n/a n/a n/a n/a 76.6 (15.6) 69.8 
(13.
1) 
-0.06 (-0.22; 0.10)
[0.461] 
Toe-brachial index, mean n/a n/a n/a n/a n/a n/a 0.5 
(0.44;0.54) 
0.5 
(0.4
7;0.
65) 
-0.08% (-0.32; 0.15) 
[0.489] 
D
ow
nloaded from
 http://ahajournals.org by on December 19, 2019
 Data are means (SD) or medians (IQR). Estimates of treatment effect are in % or absolute values (95% CI) [P values] for group difference. Models have been adjusted for baseline values of the given 
outcome and for Michigan neuropathy screening instrument (MNSI) score at baseline.  
 
Table S2. Effect of trial additionally adjusted for baseline Michigan neuropathy screening instrument (MNSI) score. 
  
  
      
 Week 1   Week 4   Week 12 
 
Active 
treatment  
Placebo 
Active vs. Placebo 
difference in change 
from baseline 
 
Active 
treatment  
Placebo 
Active vs. 
Placebo 
difference in 
change from 
baseline 
 
Active 
treatment  
Placebo 
Active vs. Placebo difference in 
change from baseline 
 
  
Primary outcome 
    
 
      
Transcutaneous oxygen tension, 
right foot (mmHg) 
49.4 (10.9) 45.5 
(8.1) 
0.66 (-0.4; 1.72)  
[0.236] 
 
17 45.8 
(14.4) 
9 51.3 (8.7) -0.26 (-0.54; 
0.02) [0.074] 
 
16 47.8 (13.3) 9 51.3 (6.7) -0.07 (-0.17; 0.02)  
[0.143] 
Transcutaneous oxygen tension, 
left foot (mmHg) 
49.2 (11.8) 47.2 
(13.4) 
1.08 (0.26; 1.89)  
[0.016] 
 
17 50.9 
(10.9) 
11 52.5 (12) 0.08 (-0.19; 
0.36) [0.55] 
 
16 51.1 (9.5) 10 51.1 (9.6) 0.01 (-0.08; 0.1)  
[0.820] 
Transcutaneous oxygen tension, 
mean (mmHg) 
49.3 (10.1) 47.6 
(11.8) 
0.95 (0.2; 1.69)  
[0.019] 
 
17 48.3 
(11.9) 
11 53 (9.9) -0.04 (-0.29; 
0.21) [0.748] 
 
16 49.4 (9.9) 10 52.1 (7.9) -0.02 (-0.1; 0.06)  
[0.609] 
Secondary outcomes 
           
Pulse wave velocity (m/s) n/a n/a n/a 
 
13 13.7 
(3.8) 
8 13.6 (4.1) -0.04% (-0.43; 
0.35) [0.829] 
 
15 (4.5) 13.4 (4) 0.09% (-0.04; 0.21)                   
[0.183] 
Toe pressure, mean (mmHg) n/a n/a n/a 
 
n/a n/a n/a 
 
16 74.1 (14.9) 10 75.5 (16.1) -0.02 (-0.2; 0.17)  
[0.848] 
Toe-brachial index, mean n/a n/a n/a 
 
n/a n/a n/a 
 
0.51 
(0.44;0.58) 
0.51 (0.43;0.65) -0.05% (-0.31; 0.21)  
[0.685] Dow
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